Breaking News
Get 40% Off 0
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas tool Copy Portfolio
Close

Immix Biopharma Inc (IMMX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Immix Biopharma's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.470 +0.220    +9.78%
17/05 - Closed. Currency in USD ( Disclaimer )
After Hours
2.330
-0.140
-5.668%
16:55:56 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 96,723
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 2.250 - 2.475
Immix Biopharma 2.470 +0.220 +9.78%

Immix Biopharma Inc Company Profile

 
Get an in-depth profile of Immix Biopharma Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

16

Equity Type

ORD

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Contact Information

Address 11400 West Olympic Boulevard Suite 200
Los Angeles, 90064
United States
Phone 310 651 8041
Fax -

Top Executives

Name Age Since Title
Magda Marquet 63 2021 Independent Director
Gabriel Morris 36 2021 CFO & Director
Sant Chawla - - Member of Scientific Advisory Board
Jane Melissa Buchan 58 2021 Independent Director
Ilya Rachman 50 2012 Co-Founder, CEO & Chairman
Heather Landau - 2023 Member of Scientific Advisory Board
Michaela Liedtke - 2023 Member of Scientific Advisory Board
Suzanne Lentzsch - 2023 Member of Scientific Advisory Board
Marko Radic - 2023 Member of Scientific Advisory Board
Vaishali Sanchorawala - - Member of Scientific Advisory Board
Helen C. Adams 64 2021 Lead Independent Director
Yekaterina Chudnovsky 38 2023 Independent Director
Gary J. Schiller - - Member of Scientific Advisory Board
George W. Sledge 72 - Member of Scientific Advisory Board
Razelle Kurzrock - - Member of Scientific Advisory Board
Larry Norton 77 - Chair of Scientific Advisory Board
Jason Hsu 49 2013 Independent Director
Galit Lahav - 2021 Member of Scientific Advisory Board
Carey J. Ng 45 2019 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

IMMX Comments

Write your thoughts about Immix Biopharma Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Esther Nyeura
Esther Nyeura Jan 04, 2022 5:26AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I need to teach me a bout this market
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email